Oral administration of imatinib to P230 BCR/ABL-expressing transgenic mice changes clones with high BCR/ABL complementary DNA expression into those with low expression

International Journal of Hematology

Volumn 84, Issue 4, 2006, Pages 346-353

  Inami, Mitsuharu ^a   Inokuchi, Koiti ^a   Yamaguchi, Hiroki ^a   Nakayama, Kazutaka ^a   Watanabe, Ayako ^a   Uchida, Naoya ^a   Tanosaki, Sakae ^a   Dan, Kazuo ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Imatinib; Megakaryocyte; Myeloproliferative disease; P230 BCR ABL; Transgenic mouse

Indexed keywords

BCR ABL PROTEIN; CD11B ANTIGEN; CD34 ANTIGEN; CD61 ANTIGEN; COMPLEMENTARY DNA; IMATINIB; STEM CELL FACTOR RECEPTOR; BCR ABL TYROSINE KINASE; BCR-ABL TYROSINE KINASE; PIPERAZINE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW; BONE MARROW SUPPRESSION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION REGULATION; MOUSE; NEUTROPHIL; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; SPLEEN; TRANSGENIC MOUSE; ANIMAL; CELL CLONE; CELL MOTION; CELL SURVIVAL; GENETICS; IMMUNOPHENOTYPING; MEGAKARYOCYTE; MYELOPROLIFERATIVE DISORDER; ORAL DRUG ADMINISTRATION; PATHOLOGY; SPLENOMEGALY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANIMALS; CELL MOVEMENT; CELL SURVIVAL; CLONE CELLS; DNA, COMPLEMENTARY; IMMUNOPHENOTYPING; MEGAKARYOCYTES; MICE; MICE, TRANSGENIC; MYELOPROLIFERATIVE DISORDERS; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; SPLENOMEGALY; TREATMENT OUTCOME;

EID: 34247233685     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.05186     Document Type: Article

References (14)

1. Quackenbush RC, Reuther GW, Miller JP, Courtney KD, Pear WS, Pendergast AM. Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases. Blood. 2000;95:2913-2921.
2. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-566.
3. le Coutre P, Mologni L, Cleris L, et al. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst. 1999;91:163-168.
4. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
5. Inokuchi K, Dan K, Takatori M, et al. Myeloproliferative disease in transgenic mice expressing P230 Bcr/Abl: longer disease latency, thrombocytosis, and mild leukocytosis. Blood. 2003;102:320-323.
6. Li S, Ilaria RL Jr, Million RP, Daley GQ, Van Etten RA. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med. 1999;189:1399-1412.
7. Cambier N, Chopra R, Strasser A, Metcalf D, Elefanty AG. BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner. Oncogene. 1998;16:335-348.
8. Calvi LM, Adams GB, Weibrecht KW, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature. 2003;425:841-846.
9. Zhang J, Niu C, Ye L, et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature. 2003;425:836-841.
10. Taichman RS. Blood and bone: two tissues whose fates are inter-twined to create the hematopoietic stem-cell niche. Blood. 2005;105:2631-2639.
11. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-652.
12. Wolff NC, Ilaria RL Jr. Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571. Blood. 2001;98:2808-2816.
13. Ren R. The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model. Oncogene. 2002;21:8629-8642.
14. Ilaria RL Jr. Animal models of chronic myelogenous leukemia. Hematol Oncol Clin North Am. 2004;18:525-543, vii.